July 28, 2015 / 6:45 AM / 3 years ago

Sanofi links with Regeneron in $2.2 billion cancer drug push

A logo is seen in front of the entrance at the headquarters French drugmaker Sanofi in Paris October 30, 2014. REUTERS/Christian Hartmann

(Reuters) - French drugmaker Sanofi (SASY.PA) said on Tuesday it was committing up to $2.17 billion to a collaboration with its long-time partner Regeneron Pharmaceuticals (REGN.O) in the hot area of cancer immunotherapy.

Sanofi will make an upfront payment of $640 million to Regeneron and the U.S. biotech company will get up to $375 million more if certain sales targets are hit. Sanofi will also invest more than $1 billion in research for the program, which aims to tap the body’s immune system to help fight cancer.

As part of the agreement, the two companies will jointly develop a programed cell death protein 1 (PD-1) inhibitor currently in Phase I clinical testing, and plan to start trials in 2016 with new drug candidates.

Reporting by Ben Hirschler; editing by David Clarke

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below